Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer

Citations

WEB OF SCIENCE

36
Citations

SCOPUS

47

초록

Lung cancer is the most common solid tumor in critically ill cancer patients admitted to intensive care units and is associated with a poor prognosis. Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor, which is active for advanced non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements. We report three cases of NSCLC patients who required mechanical ventilation for respiratory failure and were successfully weaned from mechanical ventilation after treatment with ALK inhibitors. These responses were accompanied by minimal toxicities and an overt improvement in performance status. These results suggest that ALK inhibitors may be safe and effective in critically ill patients on mechanical ventilation for respiratory failure resulting from EML4-ALK translocated NSCLC progression.

키워드

Non-small-cell lung carcinoma; Crizotinib; Mechanical ventilation; Weaning; INTENSIVE-CARE-UNIT; MALIGNANCIES; CHEMOTHERAPY
제목
Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer
저자
Ahn, Hee Kyung; Jeon, Kyeongman; Yoo, Hongseok; Han, Boram; Lee, Su Jin; Park, Hyeyon; Lee, Min Ji; Ha, Sang Yun; Han, Joung Ho; Sun, Jong-Mu; Ahn, Jin Seok; Ahn, Myung-Ju; Park, Keunchil
DOI
10.1097/JTO.0b013e3182746772
발행일
2013-02
유형
Article
저널명
Journal of Thoracic Oncology
권
8
호
2
페이지
250 ~ 253